PTC Therapeutics - Company & Market Research Reports

PTC Therapeutics is a biopharmaceutical company that focuses on the development and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company's lead product candidate is Translarna (ataluren), which is for the treatment of of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is currently in Phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.


Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017

  • Report
  • 79 Pages
From
Global Duchenne Muscular Dystrophy Therapeutics Market By Drug, By Therapeutic Approach Clinical Trial Assessment & Pipeline Analysis Outlook 2022 - Product Thumbnail Image

Global Duchenne Muscular Dystrophy Therapeutics Market By Drug, By Therapeutic Approach Clinical Trial Assessment & Pipeline Analysis Outlook 2022

  • Report
  • 100 Pages
From
Market Spotlight: Duchenne Muscular Dystrophy (DMD) - Product Thumbnail Image

Market Spotlight: Duchenne Muscular Dystrophy (DMD)

  • Report
  • 35 Pages
From
Becker Muscular Dystrophy - Pipeline Review, H1 2018 - Product Thumbnail Image

Becker Muscular Dystrophy - Pipeline Review, H1 2018

  • Report
  • 46 Pages
From
Duchenne Muscular Dystrophy - Pipeline Review, H1 2018 - Product Thumbnail Image

Duchenne Muscular Dystrophy - Pipeline Review, H1 2018

  • Report
  • 305 Pages
From
Duchenne Muscular Dystrophy (DMD): Competitive Landscape to 2026 - Product Thumbnail Image

Duchenne Muscular Dystrophy (DMD): Competitive Landscape to 2026

  • Report
  • 49 Pages
From
Polyarticular Juvenile Idiopathic Arthritis (PJIA) Global Clinical Trials Review, H1, 2018 - Product Thumbnail Image

Polyarticular Juvenile Idiopathic Arthritis (PJIA) Global Clinical Trials Review, H1, 2018

  • Clinical Trials
  • 70 Pages
From
Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 149 Pages
From
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 68 Pages
From
Cancer Stem Cell Therapies Market, 2017-2030 - Product Thumbnail Image

Cancer Stem Cell Therapies Market, 2017-2030

  • Report
  • 270 Pages
From
Dravet Syndrome: Drug Development Pipeline Study, H1 2018 - Product Thumbnail Image

Dravet Syndrome: Drug Development Pipeline Study, H1 2018

  • Report
  • 46 Pages
From
Global Antibiotics Market 2017-2021 - Product Thumbnail Image

Global Antibiotics Market 2017-2021

  • Report
  • 118 Pages
From
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape - Product Thumbnail Image

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

  • Report
  • 120 Pages
From
Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018 - Product Thumbnail Image

Epilepsy- Competitive Landscape, Market and Pipeline Analysis, 2018

  • Drug Pipelines
  • 147 Pages
From
Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H1 2018 - Product Thumbnail Image

Huntingtin (Huntington Disease Protein or HTT) - Pipeline Review, H1 2018

  • Report
  • 60 Pages
From
Epilepsy - Pipeline Review, H1 2018 - Product Thumbnail Image

Epilepsy - Pipeline Review, H1 2018

  • Report
  • 418 Pages
From
Huntington Disease - Pipeline Review, H2 2017 - Product Thumbnail Image

Huntington Disease - Pipeline Review, H2 2017

  • Report
  • 287 Pages
From
Huntington Disease - Pipeline Review, H1 2017 - Product Thumbnail Image

Huntington Disease - Pipeline Review, H1 2017

  • Report
  • 299 Pages
From
PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2026 - Product Thumbnail Image

PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2026

  • Report
  • 299 Pages
From
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 67 Pages
From
Loading Indicator
adroll